FDA Issues Mercury Amalgam Filling Warning, Group Calls For Even More Protection

The International Academy of Oral Medicine and Toxicology (IAOMT) is commending the Food and Drug Administration (FDA) for its statement yesterday that warns high-risk groups about the potential for adverse health outcomes from dental amalgam mercury fillings. However, the IAOMT, who has demanded more stringent protection from dental mercury for more than three decades, is now calling on the FDA for even more protection for all dental patients.

All silver-colored fillings, also called dental amalgams, contain approximately 50% mercury, and the FDA has just warned high-risk populations to avoid getting these fillings.

Yesterday, the FDA updated its recommendations concerning dental amalgam fillings and cautioned that “harmful health effects of mercury vapor released from the device” could impact high-risk populations. Susceptible groups advised to avoid getting mercury amalgam fillings include pregnant women and fetuses; women planning to become pregnant; nursing women and their newborns and infants; children; people with neurological disease such as multiple sclerosis, Alzheimer’s disease or Parkinson’s disease; people with impaired kidney function; and people with known heightened sensitivity (allergy) to mercury or other components of dental amalgam.

“This is certainly a step in the right direction,” Jack Kall, DMD, IAOMT Executive Chairperson of the Board stated. “But mercury shouldn’t be placed in anyone’s mouth. All dental patients need to be protected, and dentists and their staff also need to be protected from working with this toxic substance.”

Dr. Kall is among a number of IAOMT member dentists and researchers who have testified to the FDA about the dangers of dental amalgam over the course of several decades. When the IAOMT was founded in 1984, the non-profit vowed to examine the safety of dental products by relying upon peer-reviewed scientific research. In 1985, after mercury vapor release from fillings was established in the scientific literature, the IAOMT issued a declaration that the placement of silver/mercury dental amalgam fillings should cease until evidence of safety could be produced. No evidence of safety was ever produced, and meanwhile, the IAOMT has collected thousands of peer-reviewed scientific research articles to support their position that dental mercury usage should end.

“Because of our advocacy for safer, evidence-based dentistry, we have finally convinced the FDA that, at a minimum, some people are at risk,” David Kennedy, DDS, IAOMT Board of Directors, asserted. “Over 45% of dentists worldwide are still estimated to be using amalgam, including a large majority of dentists for military and welfare agencies. It should not have taken 35 years to get to this point, and FDA now needs to protect everyone.”

The IAOMT has compared the delayed route in safety regulations for mercury fillings to the same scenario that occurred with cigarettes and lead-based products such as gasoline and paint. The organization is also concerned about increased mercury exposure to patients and dental professionals when amalgam fillings are removed unsafely, as well as the health risks caused by fluoride exposure.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

They Were Children First: The Unanswered Questions of the Casa Pia Mercury Trial

It is easy, after twenty years, to turn Casa Pia into an argument about regulatory classification. That would be a mistake. The people at the center of this story were children. They did not design the study. They did not write the protocol. They did not decide which material would be placed in their teeth. They did not select the investigators. They did not determine which outcomes would be measured. They did not decide which data would be available for analysis. And they did not write the regulatory rules that eventually cited the scientific record generated by their participation. Many were already vulnerable before the study began.

Learn More »

Is the Alzheimer’s Epidemic a Hidden Case of Mercury Poisoning?

In the late 1700s and 1800s, the medical literature of the Western world was remarkably silent regarding the devastating cognitive decline we now call Alzheimer’s Disease (AD). The pathologists of the Victorian era were not mere hobbyists; they were meticulous observers who cataloged rare conditions with obsessive detail.

Learn More »

How a Study Became a Regulatory Benchmark – and Why the Ground Has Shifted

In 2006, FDA staff prepared a White Paper concerning potential adverse health risks associated with mercury in dental amalgam. The agency then brought the issue before a joint advisory panel in September 2006. The panel did not simply endorse the FDA staff’s conclusion. According to the contemporaneous record, the panel voted 13–7 against accepting the FDA staff’s safety conclusion.

Learn More »